The Pulse of ACC | The first report on the U.S. commercial experience with transcatheter aortic valve replacement (TAVR) indicates that real-world procedures are consistent with previously published randomized trial data as well as other global experience, with low rates of in-hospital mortality and procedural complication rates. The report, published Nov. 17 in the Journal of the American Medical Association, looked at all U.S. TAVR cases (7,710 patients) from 224 participating hospitals enrolled in the STS/ACC TVT Registry from Nov. 2011 through May 2013. It found that device implementation success was achieved in 92 percent of cases, while in-hospital mortality occurred in 5.5 percent of patients (95 percent CI, 5.0 percent – 6.1 percent). Learn more about the registry at NCDR.com/TVT.

Keywords: Registries, United States, Cardiology Magazine

< Back to Listings